Novel Uveitis Treatment Strategies: A Discussion with Drs. Wykoff and Yeh
Media formats available:
Details
Presenters
Overview
This webinar focuses on the risk of vision loss associated with each type of uveitis, and reviews the safety and efficacy of different treatment modalities for noninfectious posterior uveitis, including corticosteroids, sustained-release implants, immunomodulatory agents, and biologics. Potential advantages of steroid administration to the suprachoroidal space will also be discussed.Supported through an educational grant from Clearside Biomedical, Inc. Learning Objectives
Upon completion of this activity, the participant should be able to: • Describe the risk of vision loss associated with each type of uveitis. • Evaluate the safety and efficacy of different treatment modalities for noninfectious posterior uveitis, including corticosteroids, sustained-release implants, immunomodulatory/immunosuppressive agents, and biologics. • Discuss the potential advantages of steroid administration to the suprachoroidal space. Accreditation
ACCREDITATION STATEMENT Evolve Medical Education LLC (Evolve) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. CREDIT DESIGNATION STATEMENT Evolve designates this enduring material for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Faculty and Disclosures
DISCLOSURE POLICY
Steven Yeh, MD, has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Grant/Research Support: Clearside Biomedical, Inc.; Regeneron Pharmaceuticals, Inc.; and Santen Pharmaceuticals. Charles C. Wykoff, MD, PhD, has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant: Alimera Sciences, Inc.; Allergan, plc; Bayer; Clearside Biomedical, Inc.; DORC International; EyePoint/pSivida; Genentech, Inc.; Notal Vision; Novartis; ONL Therapeutics; Regeneron Pharmaceuticals, Inc.; and Roche. Speaker’s Bureau: Regeneron Pharmaceuticals, Inc. Grant/Research Support: Adverum; Aerpio; Alcon; Aldeyra; Allegro Ophthalmics; Allergan, Inc.; Apellis Pharmaceuticals; Clearside Biomedical, Inc.; EyePoint/pSivida; Genentech, Inc.; Iconic Therapeutics; Johns Hopkins University; NEI; Novartis; OHR; Ophthotech Corporation; Regeneron Pharmaceuticals, Inc.; Roche; Santen Pharmaceuticals; Taiwan Liposome Company; and Tyrogenex. Editorial Support Disclosure Susan Gallagher-Pecha, director of client services and project management, Evolve Medical Education LLC, and Erin Fletcher, MIT, Evolve Medical Education LLC, have no real or apparent conflicts of interest to report. Jaya Kumar, MD, peer reviewer has no conflict of interest to report.
It is the policy of Evolve that faculty and other individuals who are in the position to control the content of this activity disclose any real or apparent conflicts of interest relating to the topics of this educational activity. Evolve has full policies in place that will identify and mitigate all conflicts of interest prior to this educational activity.Disclaimer
OFF-LABEL STATEMENT This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The opinions expressed in the educational activity are those of the faculty. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings. DISCLAIMER The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of Evolve, or Clearside Biomedical, Inc. System Requirements
- Supported Browsers (2 most recent versions):
- Google Chrome for Windows, Mac OS, iOS, and Android
- Apple Safari for Mac OS and iOS
- Mozilla Firefox for Windows, Mac OS, iOS, and Android
- Microsoft Edge for Windows
- Recommended Internet Speed: 5Mbps+
Publication Dates
Release Date:
Expiration Date:
Ready to Claim Your Credits?
You have attempts to pass this post-test. Take your time and review carefully before submitting.
Good luck!
Recommended
- CME/CE Broadcast Replay
Enhancing Collaborative Care in Retinal Diseases: A Focus on Injection Therapies
1.00 credit
Deepak Sambhara, MD
Katherine E. Talcott, MD
Roger A. Goldberg, MD, MBA
Christina Y. Weng, MD, MBA, FASRS
Katherine E. Talcott, MD
Roger A. Goldberg, MD, MBA
Christina Y. Weng, MD, MBA, FASRS
